uael domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/imagionbx/wp-includes/functions.php on line 6114kirki domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/imagionbx/wp-includes/functions.php on line 6114
Highlights • Encouraging top-line performance of world’s first molecular MRI test • Pathology results from lymph node tissue shows concordance with MRI imaging MELBOURNE —
Notice is hereby given that an Extraordinary General Meeting (EGM) of Imagion Biosystems Limited (Imagion or Company) will be held at the offices of K&L
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide highlights from
Our October Newsletter Highlights: 🔹 Scientific poster accepted at AACR Ovarian Cancer Conference 🔹 Strategic partnership signed with Prestige Biopharma for pancreatic cancer 🔹 Imagion
Highlights: Reduces operating expenses Update on MagSense® HER2 program MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it
1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
Highlights include: MagSense® HER2 Phase 1 Study achieves enrolment target Expands collaboration with Siemens Healthineers Dr. Isaac Bright appointed as CEO MELBOURNE – Imagion Biosystems (ASX:IBX),
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance